CA3090062A1 - Treatment of atopic dermatitis with moderate to severe excoriation - Google Patents
Treatment of atopic dermatitis with moderate to severe excoriation Download PDFInfo
- Publication number
- CA3090062A1 CA3090062A1 CA3090062A CA3090062A CA3090062A1 CA 3090062 A1 CA3090062 A1 CA 3090062A1 CA 3090062 A CA3090062 A CA 3090062A CA 3090062 A CA3090062 A CA 3090062A CA 3090062 A1 CA3090062 A1 CA 3090062A1
- Authority
- CA
- Canada
- Prior art keywords
- nemolizumab
- excoriations
- weeks
- once
- equivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628714P | 2018-02-09 | 2018-02-09 | |
| US62/628,714 | 2018-02-09 | ||
| PCT/IB2019/051051 WO2019155427A1 (en) | 2018-02-09 | 2019-02-08 | Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3090062A1 true CA3090062A1 (en) | 2019-08-15 |
Family
ID=65729402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3090062A Pending CA3090062A1 (en) | 2018-02-09 | 2019-02-08 | Treatment of atopic dermatitis with moderate to severe excoriation |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12435147B2 (https=) |
| EP (2) | EP4644424A3 (https=) |
| JP (3) | JP7777921B2 (https=) |
| CN (1) | CN112040976A (https=) |
| AU (2) | AU2019219608B2 (https=) |
| BR (1) | BR112020016144A2 (https=) |
| CA (1) | CA3090062A1 (https=) |
| CL (1) | CL2020002050A1 (https=) |
| DK (1) | DK3749353T3 (https=) |
| ES (1) | ES3049513T3 (https=) |
| FI (1) | FI3749353T3 (https=) |
| HR (1) | HRP20251101T1 (https=) |
| IL (1) | IL276524A (https=) |
| LT (1) | LT3749353T (https=) |
| MX (1) | MX2020008193A (https=) |
| PH (1) | PH12020551185A1 (https=) |
| PL (1) | PL3749353T3 (https=) |
| PT (1) | PT3749353T (https=) |
| RU (1) | RU2758378C1 (https=) |
| SG (1) | SG11202007558YA (https=) |
| SI (1) | SI3749353T1 (https=) |
| TW (1) | TWI856006B (https=) |
| WO (1) | WO2019155427A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025095100A1 (ja) * | 2023-11-02 | 2025-05-08 | マルホ株式会社 | 医薬組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| EP2325316B8 (en) | 1999-06-02 | 2017-04-19 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, NR10 |
| EP1858924A1 (en) * | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| JP5954916B1 (ja) | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
| SG10202112628UA (en) * | 2015-11-30 | 2021-12-30 | Anacor Pharmaceuticals Inc | Topical pharmaceutical formulations for treating inflammatory-related conditions |
-
2019
- 2019-02-08 JP JP2020542801A patent/JP7777921B2/ja active Active
- 2019-02-08 BR BR112020016144-6A patent/BR112020016144A2/pt unknown
- 2019-02-08 PL PL19710488.8T patent/PL3749353T3/pl unknown
- 2019-02-08 EP EP25189672.6A patent/EP4644424A3/en active Pending
- 2019-02-08 LT LTEPPCT/IB2019/051051T patent/LT3749353T/lt unknown
- 2019-02-08 CN CN201980024489.7A patent/CN112040976A/zh active Pending
- 2019-02-08 RU RU2020129578A patent/RU2758378C1/ru active
- 2019-02-08 SI SI201930960T patent/SI3749353T1/sl unknown
- 2019-02-08 CA CA3090062A patent/CA3090062A1/en active Pending
- 2019-02-08 PT PT197104888T patent/PT3749353T/pt unknown
- 2019-02-08 MX MX2020008193A patent/MX2020008193A/es unknown
- 2019-02-08 ES ES19710488T patent/ES3049513T3/es active Active
- 2019-02-08 DK DK19710488.8T patent/DK3749353T3/da active
- 2019-02-08 AU AU2019219608A patent/AU2019219608B2/en active Active
- 2019-02-08 FI FIEP19710488.8T patent/FI3749353T3/fi active
- 2019-02-08 SG SG11202007558YA patent/SG11202007558YA/en unknown
- 2019-02-08 EP EP19710488.8A patent/EP3749353B1/en active Active
- 2019-02-08 WO PCT/IB2019/051051 patent/WO2019155427A1/en not_active Ceased
- 2019-02-08 HR HRP20251101TT patent/HRP20251101T1/hr unknown
- 2019-02-11 TW TW108104519A patent/TWI856006B/zh active
-
2020
- 2020-08-05 PH PH12020551185A patent/PH12020551185A1/en unknown
- 2020-08-05 IL IL276524A patent/IL276524A/en unknown
- 2020-08-07 US US16/988,554 patent/US12435147B2/en active Active
- 2020-08-07 CL CL2020002050A patent/CL2020002050A1/es unknown
-
2023
- 2023-09-21 JP JP2023155476A patent/JP2023182632A/ja active Pending
-
2025
- 2025-09-11 JP JP2025151311A patent/JP2025176134A/ja active Pending
- 2025-09-12 US US19/327,709 patent/US20260008859A1/en active Pending
-
2026
- 2026-01-13 AU AU2026200182A patent/AU2026200182A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240376210A1 (en) | Vedolizumab for the treatment of fistulizing crohn's disease | |
| JP7671822B2 (ja) | 結節性痒疹患者における皮膚病変およびそう痒の治療 | |
| US20260008859A1 (en) | Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation | |
| CA3228708A1 (en) | Treatment of atopic dermatitis | |
| TW202214297A (zh) | 用於治療疼痛之結合TGF-α及表皮調節素(EPIREGULIN)之抗體 | |
| TWI870471B (zh) | 全身性硬化症治療用醫藥組合物 | |
| HK40130865A (en) | Treatment of atopic dermatitis with moderate to severe excoriation | |
| HK40042731B (en) | Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation | |
| HK40042731A (en) | Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation | |
| CN109641053A (zh) | 给药方案 | |
| US20260078181A1 (en) | Trem-2 agonists for the treatment of marfan syndrome | |
| US20250066467A1 (en) | Methods for the treatment of myasthenia gravis | |
| RU2822134C2 (ru) | Лечение поражений кожи и зуда у пациентов с узловатой почесухой | |
| KR20260057215A (ko) | 결절성 양진 환자에서 피부 병변 및 소양증의 치료 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231214 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250127 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250127 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250620 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251016 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251203 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251209 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251209 |